Multiple Blood Culture Sampling, Proper Antimicrobial Choice, and Adequate Dose in Definitive Therapy Supported by the Antimicrobial Stewardship Team Could Decrease 30-Day Sepsis Mortality Rates

References

• Campion M, Scully G. Antibiotic use in the intensive care unit: optimization and De-Escalation. J Intensive Care Med. 2018;33:647–655. doi:10.1177/0885066618762747
   PubMed Web of Science ®Google Scholar
• CDC. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. Available from: https://www.cdc.gov/antibiotic-use/core-elements/hospital.html. Accessed January 16, 2023.
   Google Scholar
• Seok H, Jeon JH, Park DW. Antimicrobial Therapy and antimicrobial stewardship in sepsis. Infect Chemother. 2020;52:19–30. doi:10.3947/ic.2020.52.1.19
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2000;38:151–157. doi:10.1016/s0732-8893(00)00185-1
   PubMed Web of Science ®Google Scholar
• Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:762–774. doi:10.1001/jama.2016.0288
   PubMed Web of Science ®Google Scholar
• Oda K. Development of software for antimicrobial PK/PD simulation incorporating Montecarlo simulation based on Microsoft® Office Excel. Iryo Yakugaku. 2011;37:335–344. doi:10.5649/jjphcs.37.335
   Google Scholar
• Yamada T, Minami K, Oda K, et al. Probability of target attainment of oral antimicrobials for Escherichia coli and Klebsiella pneumoniae based on Monte Carlo simulations. Diagn Microbiol Infect Dis. 2022;103:115662. doi:10.1016/j.diagmicrobio.2022.115662
   PubMed Web of Science ®Google Scholar
• Yamada T, Ooi Y, Oda K, et al. Observational study to determine the optimal dose of daptomycin based on pharmacokinetic/pharmacodynamic analysis. J Infect Chemother. 2020;26:379–384. doi:10.1016/j.jiac.2019.11.002
   PubMed Web of Science ®Google Scholar
• Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36(Supplement 1):S42–50. doi:10.1086/344653
   PubMedGoogle Scholar
• Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother. 1999;43:672–677. doi:10.1128/AAC.43.3.672
   PubMed Web of Science ®Google Scholar
• Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073–1081. doi:10.1128/AAC.37.5.1073
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925–942. doi:10.2165/00003088-200443130-00005
   PubMed Web of Science ®Google Scholar
• Yasuhara M, Iga T, Zenda H, et al. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit. 1998;20:139–148. doi:10.1097/00007691-199804000-00003
   PubMed Web of Science ®Google Scholar
• Ogawa R, Kobayashi S, Sasaki Y, et al. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection. Int J Clin Pharmacol Ther. 2013;51:357–366. doi:10.5414/CP201739
   PubMed Web of Science ®Google Scholar
• Assandri A, Bernareggi A. Binding of teicoplanin to human serum albumin. Eur J Clin Pharmacol. 1987;33:191–195. doi:10.1007/BF00544566
   PubMed Web of Science ®Google Scholar
• Sasaki T, Takane H, Ogawa K, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother. 2011;55:1867–1873. doi:10.1128/AAC.01185-10
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Hiraki Y, Matsumoto K, et al. Pharmacokinetics and protein binding of linezolid in cerebrospinal fluid and serum in a case of post-neurosurgical bacterial meningitis. Scand J Infect Dis. 2011;43:982–985. doi:10.3109/00365548.2011.600327
   PubMed Web of Science ®Google Scholar
• Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47:2775–2780. doi:10.1128/AAC.47.9.2775-2780.2003
   PubMed Web of Science ®Google Scholar
• Xuan D, Nicolau DP, Nightingale CH. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Int J Antimicrob Agents. 2004;23:291–295. doi:10.1016/j.ijantimicag.2003.07.010
   PubMed Web of Science ®Google Scholar
• Ng PK. Determining aminoglycoside dosage and blood levels using a programmable calculator. Am J Hosp Pharm. 1980;37:225–231.
   PubMedGoogle Scholar
• Kirby WM, Clarke JT, Libke RD, et al. Clinical pharmacology of amikacin and kanamycin. J Infect Dis. 1976;134:S312–5. doi:10.1093/infdis/135.supplement_2.s312
   PubMed Web of Science ®Google Scholar
• Madaras-Kelly K, Jones M, Remington R, et al. Development of an antibiotic spectrum score based on Veterans Affairs culture and susceptibility data for the purpose of measuring antibiotic de-escalation: a modified Delphi approach. Infect Control Hosp Epidemiol. 2014;35:1103–1113. doi:10.1086/677633
   PubMed Web of Science ®Google Scholar
• Imaeda T, Nakada TA, Takahashi N, et al. Trends in the incidence and outcome of sepsis using data from a Japanese nationwide medical claims database-The Japan Sepsis Alliance (JaSA) study group. Crit Care. 2021;25:338. doi:10.1186/s13054-021-03762-8
   PubMed Web of Science ®Google Scholar
• Zitek T, Bourne M, Raber J, et al. Blood culture results and overtreatment associated with the use of a 1-hour sepsis bundle. J Emerg Med. 2020;59:629–636. doi:10.1016/j.jemermed.2020.06.055
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med. 2014;40:32–40. doi:10.1007/s00134-013-3077-7
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317. doi:10.1086/421946
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45:486–552. doi:10.1097/CCM.0000000000002255
   PubMed Web of Science ®Google Scholar
• Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4:1065–1074. doi:10.1517/17425255.4.8.1065
   PubMed Web of Science ®Google Scholar
• Wong VK, Wright HT, Ross LA, et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J. 1991;10:122–125. doi:10.1097/00006454-199102000-00009
   PubMed Web of Science ®Google Scholar
• Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America. Clin Infect Dis. 2016;62:e51–77. doi:10.1093/cid/ciw118
   PubMed Web of Science ®Google Scholar
• Ruiz J, Ramirez P, Gordon M, et al. Antimicrobial stewardship programme in critical care medicine: a prospective interventional study. Med Intensiva. 2018;42:266–273. doi:10.1016/j.medin.2017.07.002
   PubMed Web of Science ®Google Scholar
• Tabah A, Bassetti M, Kollef MH, et al. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Med. 2020;46:245–265. doi:10.1007/s00134-019-05866-w
   PubMed Web of Science ®Google Scholar
• Weiss E, Zahar JR, Lesprit P, et al. Elaboration of a consensual definition of de-escalation allowing a ranking of beta-lactams. Clin Microbiol Infect. 2015;21:649.e1–10. doi:10.1016/j.cmi.2015.03.013
   PubMed Web of Science ®Google Scholar
• Japan nosocomial infection surveillance (JANIS). Annual Report of Public Information for January to December 2020. Available from: https://janis.mhlw.go.jp/report/open_report/2020/3/1/ken_Open_Report_202000_200over.pdf. Accessed January 16, 2023.
   Google Scholar
• Leone M, Bechis C, Baumstarck K, et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med. 2014;40:1399–1408. doi:10.1007/s00134-014-3411-8
   PubMed Web of Science ®Google Scholar
• Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49:e1063–143. doi:10.1097/CCM.0000000000005337
   PubMed Web of Science ®Google Scholar
• Tabah A, Cotta MO, Garnacho-Montero J, et al. A systematic review of the definitions, determinants, and clinical outcomes of antimicrobial de-escalation in the intensive care unit. Clin Infect Dis. 2016;62:1009–1017. doi:10.1093/cid/civ1199
   PubMed Web of Science ®Google Scholar